共 50 条
- [1] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors[J]. Nature Communications, 13Xiao-Li WeiFu-Rong LiuJi-Hong LiuHong-Yun ZhaoYang ZhangZhi-Qiang WangMiao-Zhen QiuFei XuQiu-Qiong YuYi-Wu DuYan-Xia ShiDe-Sheng WangFeng-Hua WangRui-Hua Xu
- [2] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors[J]. NATURE COMMUNICATIONS, 2022, 13 (01)Wei, Xiao-LiLiu, Fu-RongLiu, Ji-HongZhao, Hong-YunZhang, YangWang, Zhi-QiangQiu, Miao-ZhenXu, FeiYu, Qiu-QiongDu, Yi-WuShi, Yan-XiaWang, De-ShengWang, Feng-HuaXu, Rui-Hua
- [3] A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, in patients (pts) with advanced solid tumours[J]. ANNALS OF ONCOLOGY, 2021, 32 : S14 - S14Wei, X-L.Liu, J-H.Zhao, H.Zhang, Y.Liu, Q-W.Zou, B-Y.Wang, F.Wang, Z-Q.Qiu, M-Z.Yu, Q-Q.Du, Y-W.Xu, R-H.
- [4] First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors[J]. CLINICAL CANCER RESEARCH, 2015, 21 (01) : 77 - 86Sarker, DebashisAng, Joo ErnBaird, RichardKristeleit, RebeccaShah, KrunalMoreno, VictorClarke, Paul A.Raynaud, Florence I.Levy, GalliaWare, Joseph A.Mazina, KathrynLin, RayWu, JennyFredrickson, JillSpoerke, Jill M.Lackner, Mark R.Yan, YibingFriedman, Lori S.Kaye, Stan B.Derynck, Mika K.Workman, Paulde Bono, Johann S.
- [5] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Li, JinXu, NongLiu, TianshuHuang, JianjinYin, YongmeiMou, HaiboZhang, JunWu, LihuaLiu, Zong LiangBao, HanyingXu, Zusheng
- [6] A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Wagner, A. J.Bendell, J. C.Dolly, S.Morgan, J. A.Ware, J. A.Fredrickson, J.Mazina, K. E.Lauchle, J. O.Burris, H. A.De Bono, J. S.
- [7] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Burris, H.Rodon, J.Sharma, S.Herbst, R. S.Tabernero, J.Infante, J. R.Silva, A.Demanse, D.Hackl, W.Baselga, J.
- [8] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors[J]. CANCER, 2018, 124 (02) : 315 - 324Bedard, Philippe L.Davies, Michael A.Kopetz, ScottJuric, DejanShapiro, Geoffrey I.Luke, Jason J.Spreafico, AnnaWu, BinCastell, ChristelleGomez, CorinneCartot-Cotton, SylvaineMazuir, FlorentDubar, MichelMicallef, SandrineDemers, BrigitteFlaherty, Keith T.
- [9] Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells[J]. Cell Death & Disease, 12Yu-xiang WangXu ZhangQing-yang MaLan-dian HuXi ZhangYi WangLan XuChun-hao YangCun TanXiang-yin KongJian DingLing-hua Meng
- [10] A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Hong, David S.Moore, Kathleen N.Bendell, Johanna C.Karp, Daniel D.Wang, Judy Sing-ZanUlahannan, Susanna VarkeyJohnson, Melissa LynneAljumaily, RaidHynes, ScottCallies, SophieDecker, RodneyLaBell, ElizabethNiland, MicheleWang, Xuejing AimeeLin, Aimee BencePatel, Manish R.